Cancer diagnostics News and Research

RSS

Preliminary discovery may help individualize prostate cancer screening in the future

Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.

5 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Study finds continued smoking after cancer diagnosis among patients, family caregivers

Nicotine is so addictive for many people that even a cancer diagnosis doesn't help them - or their family members and caregivers - throw the cigarettes away.

31 Mar 2011

Top-line results from Biomoda's CyPath pilot study against lung cancer

Cancer diagnostics company Biomoda, Inc. today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath's ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.

31 Mar 2011

CCAC National Survey finds 82% of Canadians with cancer

The Colorectal Cancer Association of Canada today announced findings from the Weighing Quality of Life in Cancer National Survey showing that an alarming 82 per cent of Canadians have been touched closely by cancer and have had a close friend or family member battle cancer, or have done so themselves.

31 Mar 2011

Nanotechnology-based biosensor may allow early cancer, pathogen detection

A nanotechnology-based biosensor being developed by Kansas State University researchers may allow early detection of both cancer cells and pathogens, leading to increased food safety and reduced health risks.

30 Mar 2011

New study: Many elderly men may overuse PSA testing

A new study on the use of prostate-specific antigen-based prostate cancer screening in the United States found that many elderly men may be undergoing unnecessary prostate cancer screenings.

29 Mar 2011

Concord Medical fourth quarter total net revenues increase 30.1% to RMB112.9 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2010.

28 Mar 2011

Longer Looks: Behind the hospital money curtain; Medical data breaches

Think you would stick to a diet if someone paid you for it? Would you be more likely to exercise if you were fined each time you bailed on your scheduled workout? Research in recent years suggests—and a handful of new businesses are betting—that you might.

25 Mar 2011

CABC offers first-ever PEM-guided accessory for breast biopsy

The Center for Advanced Breast Care is the first comprehensive breast center in the Chicago area to add Positron Emission Mammography-guided biopsy capability to its already extensive breast cancer care services.

23 Mar 2011

Breast cancer updates

Many survivors of breast cancer cite stress as a link to the cancer despite no scientific proof of a connection. Experts believe that the root cause here are the lifestyle-related issues - such as smoking and obesity - where there is a clear link to the cancer.

22 Mar 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

Ventana, CST enter license agreement for personalized cancer diagnostics

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.

From Cell Signaling Technology 16 Mar 2011

Prophylactic PEG placement prior to HNC therapy associated with high rate of non use

Impairment of oral intake occurs in the majority of patients with head and neck cancer (HNC) receiving chemoradiotherapy. Placement of prophylactic percutaneous endoscopic gastrostomy (PEG) tube in asymptomatic newly diagnosed HNC before chemoradiation is a common practice in some centers. In some studies, PEG has been associated with a decrease in treatment related weight loss in patients with HNC, but no studies have examined the utilization rate.

16 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

Cancer Research UK introduces new centre in Oxford

A new centre launched today will cement Oxford's place at the forefront of cancer research, and form one of the final links in a unique chain of Cancer Research UK Centres across the country.

15 Mar 2011

Study: Statin use may reduce risk of high-grade prostate cancer

Men who take a certain class of cholesterol-lowering medicine, otherwise known as statins, may be 60 percent less likely to be diagnosed with high-grade prostate cancer.

15 Mar 2011

DiagnoCure first quarter total revenue is $362,101 for 2011

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the first quarter of fiscal 2011.

11 Mar 2011

NCI report: Number of US cancer survivors increases to 11.7 million during 2007

The number of cancer survivors in the United States increased to 11.7 million in 2007, according to a report released by the Centers for Disease Control and Prevention and the National Cancer Institute, part of the National Institutes of Health. There were 3 million cancer survivors in 1971 and 9.8 million in 2001.

10 Mar 2011

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Biotechnology company MabCure, Inc. is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists.

9 Mar 2011